P-OGC54 Economic cost utility analysis of stage directed oesophageal adenocarcinoma treatment

Abstract Background Oesophageal Cancer (OC) treatment levies substantial financial burden on Health Services and Best Supportive Care (BSC) outcomes are poor. Potentially Curative Surgery with or without Chemotherapy is offered to patients locally advanced disease this study aimed examine costs related life-years gained in having potentially curative (oesophagectomy) those receiving (BSC). Methods Consecutive 179 diagnosed adenocarcinoma of the oesophagus between 2010 2017 were classified according modality by intention treat (surgery vs. neoadjuvant/adjuvant chemotherapy). Cost calculations for one-year’s from referral made network diagnostic, staging, algorithms. Primary outcome was Overall Survival (OS). Results OC median survival after BSC reported be 3 months costing £4391 compared Oesophagectomy (all stages) 44 an average £26,652 one year’s treatment: cost per QALY £92,448 £12,207.20 surgery. incurred stage I £25,153.09, II £26,795.17, III £28,781.81, IV £28,592.64. Based these values, Quality Adjusted Life Year (QALY) - £8,361, £12,319, £21,998 £35,011. Conclusions that included oesophagectomy improved OS fifteen-fold effective at national thresholds readiness pay QALY.